| CNVkit: genome-wide copy number detection and visualization from targeted DNA sequencing E Talevich, AH Shain, T Botton, BC Bastian PLoS computational biology 12 (4), e1004873, 2016 | 1482 | 2016 |
| Kinase fusions are frequent in Spitz tumours and spitzoid melanomas T Wiesner, J He, R Yelensky, R Esteve-Puig, T Botton, I Yeh, D Lipson, ... Nature communications 5 (1), 3116, 2014 | 592 | 2014 |
| Metformin inhibits melanoma development through autophagy and apoptosis mechanisms T Tomic, T Botton, M Cerezo, G Robert, F Luciano, A Puissant, P Gounon, ... Cell death & disease 2 (9), e199-e199, 2011 | 342 | 2011 |
| Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway AH Shain, M Garrido, T Botton, E Talevich, I Yeh, JZ Sanborn, J Chung, ... Nature genetics 47 (10), 1194-1199, 2015 | 255 | 2015 |
| Mitf is the key molecular switch between mouse or human melanoma initiating cells and their differentiated progeny Y Cheli, S Guiliano, T Botton, S Rocchi, V Hofman, P Hofman, ... Oncogene 30 (20), 2307-2318, 2011 | 248 | 2011 |
| Activating MET kinase rearrangements in melanoma and Spitz tumours I Yeh, T Botton, E Talevich, AH Shain, AJ Sparatta, A de La Fouchardiere, ... Nature communications 6 (1), 7174, 2015 | 242 | 2015 |
| Compounds triggering ER stress exert anti-melanoma effects and overcome BRAF inhibitor resistance M Cerezo, A Lehraiki, A Millet, F Rouaud, M Plaisant, E Jaune, T Botton, ... Cancer cell 29 (6), 805-819, 2016 | 236 | 2016 |
| NTRK3 kinase fusions in Spitz tumours I Yeh, MK Tee, T Botton, AH Shain, AJ Sparatta, A Gagnon, SS Vemula, ... The Journal of pathology 240 (3), 282-290, 2016 | 143 | 2016 |
| Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy T Botton, I Yeh, T Nelson, SS Vemula, A Sparatta, MC Garrido, M Allegra, ... Pigment cell & melanoma research 26 (6), 845-851, 2013 | 128 | 2013 |
| Bi-allelic loss of CDKN2A initiates melanoma invasion via BRN2 activation H Zeng, A Jorapur, AH Shain, UE Lang, R Torres, Y Zhang, AS McNeal, ... Cancer cell 34 (1), 56-68. e9, 2018 | 125 | 2018 |
| Genetic heterogeneity of BRAF fusion kinases in melanoma affects drug responses T Botton, E Talevich, VK Mishra, T Zhang, AH Shain, C Berquet, ... Cell reports 29 (3), 573-588. e7, 2019 | 73 | 2019 |
| Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion AM Menzies, I Yeh, T Botton, BC Bastian, RA Scolyer, GV Long Pigment cell & melanoma research 28 (5), 607, 2015 | 72 | 2015 |
| In vitro and in vivo anti-melanoma effects of ciglitazone T Botton, A Puissant, P Bahadoran, JS Annicotte, L Fajas, JP Ortonne, ... Journal of Investigative Dermatology 129 (5), 1208-1218, 2009 | 69 | 2009 |
| Ciglitazone negatively regulates CXCL1 signaling through MITF to suppress melanoma growth T Botton, A Puissant, Y Cheli, T Tomic, S Giuliano, L Fajas, M Deckert, ... Cell Death & Differentiation 18 (1), 109-121, 2011 | 43 | 2011 |
| CNVkit: Copy number detection and visualization for targeted sequencing using off-target reads E Talevich, AH Shain, T Botton, BC Bastian BioRxiv, 010876, 2014 | 24 | 2014 |
| Discovery of a new molecule inducing melanoma cell death: dual AMPK/MELK targeting for novel melanoma therapies E Jaune, E Cavazza, C Ronco, O Grytsai, P Abbe, N Tekaya, M Zerhouni, ... Cell Death & Disease 12 (1), 64, 2021 | 18 | 2021 |
| Rac1 dynamics in the human opportunistic fungal pathogen Candida albicans R Vauchelles, D Stalder, T Botton, RA Arkowitz, M Bassilana PLoS One 5 (10), e15400, 2010 | 18 | 2010 |
| Melanoma BRAF fusions T Botton, I Yeh, BC Bastian Clinical Cancer Research 20 (24), 6631-6631, 2014 | 6 | 2014 |
| Hybrid Capture‐Based Tumor Sequencing and Copy Number Analysis to Confirm Origin of Metachronous Metastases in BRCA1‐Mutant Cholangiocarcinoma Harboring a … HC Lim, M Montesion, T Botton, EA Collisson, SE Umetsu, SC Behr, ... The oncologist 23 (9), 998-1003, 2018 | 2 | 2018 |
| Comment on ‘Testing for BRAF fusions in patients with advanced BRAF/NRAS/KIT wild-type melanomas permits to identify patients who could benefit of anti-MEK targeted therapy’ T Botton, T Passeron, S Rocchi Journal of Clinical Pathology 73 (8), 524-525, 2020 | 1 | 2020 |
